Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY6 | Q15077 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 5/20 | 0.47 |
| ▸ | CA12 | O43570 | 4/20 | 0.45 |
| ▸ | CA1 | P00915 | 4/20 | 0.45 |
| ▸ | CA2 | P00918 | 4/20 | 0.45 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.44 |
| ▸ | ALB | P02768 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL92536 | 0.89 | USP2 (0.62) | P2RY6USP2L3MBTL1ESR1CA9 | |
| SCHEMBL13974887 | 0.84 | USP2 (0.47) | P2RY6USP2L3MBTL1ESR1CA9 | |
| SCHEMBL16926675 | 0.82 | USP2 (0.56) | P2RY6USP2L3MBTL1ESR1CA9 | |
| SCHEMBL10205417 | 0.79 | USP2 (0.58) | USP2L3MBTL1CA9CA12CA1 | |
| SCHEMBL3289756 | 0.79 | FOLH1 (0.62) | USP2L3MBTL1ESR1CA9CA12 | |
| SCHEMBL10153957 | 0.78 | USP2 (0.66) | USP2L3MBTL1ESR1CA9CA12 | |
| SCHEMBL14852664 | 0.78 | CA9 (0.58) | USP2L3MBTL1CA9CA12CA1 | |
| SCHEMBL18799655 | 0.78 | USP2 (0.57) | USP2L3MBTL1ESR1CA9CA12 | |
| SCHEMBL23258882 | 0.77 | USP2 (0.63) | USP2L3MBTL1ESR1CA9CA12 | |
| SCHEMBL16153102 | 0.76 | USP2 (0.64) | USP2L3MBTL1ESR1CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215635-A1 | LABELLING STRATEGIES FOR THE SENSITIVE DETECTION OF ANALYTES | BASF SE (DE) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215635-A1 | LABELLING STRATEGIES FOR THE SENSITIVE DETECTION OF ANALYTES | MTREX, ADAR, GUSB | P2RY6 3852/4885USP2 816/4885L3MBTL1 445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.